NIRSEVIMAB has been approved by the US FDA as the first RSV prevention measure for all infant populations
The US Food and Drug Administration (FDA) has announced the approval of a monoclonal antibody nirsevimab for the prevention of respiratory syncytial virus (RSV) related lower respiratory diseases in all infant populations.The FDA approves nirsevimab for the prevention of lower respiratory tract diseases caused by RSV in infants and young children: newborns and infants who are about to enter or are born during the first RSV infection season, as well as children who are still susceptible to severe RSV diseases within 24 months of age during the second RSV infection season...
China Center for Disease Control and Prevention released the monitoring of monkeypox epidemic in June
On July 14th, the China Center for Disease Control and Prevention released the monitoring of monkeypox epidemic in mainland China in June. The monitoring results show that from June 2 to June 30, 2023, there were 106 new confirmed cases of monkeypox reported in mainland China (excluding Hong Kong, Macao, and Taiwan), including 48 cases reported in Guangdong Province, 45 cases reported in Beijing City, 8 cases reported in Jiangsu Province, 2 cases reported in Hubei Province, 2 cases reported in Shandong Province, and 1 case reported in Zhejiang Province...